Schreuder MM, Badal R, Boersma E, et al. - To compare a high potent P2Y₁₂ inhibitor + aspirin with clopidogrel + aspirin among patients having acute coronary syndrome, researchers undertook a gender-specific analysis of the pooled efficacy as well as safety data of clinical trials. Via a systematic literature search, they identified randomized clinical trials that compared patients after percutaneous coronary intervention/acute coronary syndrome who were receiving high potent P2Y₁₂ inhibitors + aspirin vs clopidogrel + aspirin. Overall 6 randomized clinical trials with 43,990 patients (13,030 women) and with a median follow-up time of 1.06 years were analyzed. For major cardiovascular events, similar relative risk reduction was evident in women and men. As far as safety is concerned, males and females had similar risk of major bleeding by high-potency dual antiplatelet therapy. Overall, differential dual antiplatelet therapy treatment for both genders is not justified in view of the identified small and statistically insignificant variation in efficacy and safety estimates of high-potency dual antiplatelet therapy between males and females after percutaneous coronary intervention/acute coronary syndrome.